200 related articles for article (PubMed ID: 15592327)
1. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Vormfelde SV; Engelhardt S; Zirk A; Meineke I; Tuchen F; Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2004 Dec; 76(6):557-66. PubMed ID: 15592327
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
Vormfelde SV; Schirmer M; Toliat MR; Meineke I; Kirchheiner J; Nürnberg P; Brockmöller J
Pharmacogenomics J; 2007 Jun; 7(3):200-11. PubMed ID: 16969365
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
5. Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Werner D; Werner U; Meybaum A; Schmidt B; Umbreen S; Grosch A; Lestin HG; Graf B; Zolk O; Fromm MF
Clin Pharmacokinet; 2008; 47(5):323-32. PubMed ID: 18399713
[TBL] [Abstract][Full Text] [Related]
6. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
10. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.
Vormfelde SV; Toliat MR; Schirmer M; Meineke I; Nürnberg P; Brockmöller J
Clin Pharmacol Ther; 2008 Jun; 83(6):815-7. PubMed ID: 18043684
[No Abstract] [Full Text] [Related]
11. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
12. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
[TBL] [Abstract][Full Text] [Related]
14. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
Uchida S; Shimada K; Misaka S; Imai H; Katoh Y; Inui N; Takeuchi K; Ishizaki T; Yamada S; Ohashi K; Namiki N; Watanabe H
Drug Metab Pharmacokinet; 2010; 25(6):605-10. PubMed ID: 20962433
[TBL] [Abstract][Full Text] [Related]
15. Heritability of metoprolol and torsemide pharmacokinetics.
Matthaei J; Brockmöller J; Tzvetkov MV; Sehrt D; Sachse-Seeboth C; Hjelmborg JB; Möller S; Halekoh U; Hofmann U; Schwab M; Kerb R
Clin Pharmacol Ther; 2015 Dec; 98(6):611-21. PubMed ID: 26344676
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of acenocoumarol pharmacodynamics.
Morin S; Bodin L; Loriot MA; Thijssen HH; Robert A; Strabach S; Verstuyft C; Tregouet DA; Dubert L; Laurent-Puig P; Funck-Brentano C; Jaillon P; Beaune PH; Becquemont L
Clin Pharmacol Ther; 2004 May; 75(5):403-14. PubMed ID: 15116053
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.
Kirchheiner J; Ufer M; Walter EC; Kammerer B; Kahlich R; Meisel C; Schwab M; Gleiter CH; Rane A; Roots I; Brockmöller J
Pharmacogenetics; 2004 Jan; 14(1):19-26. PubMed ID: 15128047
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.
Ufer M; Kammerer B; Kahlich R; Kirchheiner J; Yasar U; Brockmöller J; Rane A
Xenobiotica; 2004 Sep; 34(9):847-59. PubMed ID: 15742978
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.
Kirchheiner J; Störmer E; Meisel C; Steinbach N; Roots I; Brockmöller J
Pharmacogenetics; 2003 Aug; 13(8):473-80. PubMed ID: 12893985
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
